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Abstract 
Objective Adverse effects of hypercaloric, high fructose diets on insulin sensitivity and lipids 
in human subjects have been shown repeatedly. The implications of fructose in amounts close 
to usual daily consumption however, have not been well studied. The study aim was to assess 
the effect of moderate amounts of fructose and sucrose compared to glucose on glucose and 
lipid metabolism. 
Research Design and Methods Nine healthy, normal weight male volunteers (age 19-25 
years) were studied in this double blind, randomized cross-over trial. All subjects consumed 
four different sweetened beverages (600 ml/day) for three weeks each: medium fructose (MF, 
40 g/day), high fructose (HF), high glucose (HG) and high sucrose (HS) (each 80 g/day). 
Euglycemic-hyperinsulinemic clamps with [6,6]-
2
H2 glucose labeling were used to measure 
endogenous glucose production. Lipid profile, glucose and insulin were measured in fasting 
samples. 
Results Hepatic suppression of glucose production during the clamp was significantly lower 
after HF (59.4±11.0%) compared to HG (70.3±10.5%, p<0.05), while fasting glucose, insulin 
and C-peptide did not differ between the interventions. Compared to HG, both LDL 
cholesterol and total cholesterol were significantly higher after MF, HF and HS and free fatty 
acids were significantly increased after MF but not after the two other interventions (p<0.05). 
Subjects’ energy intake during the interventions did not differ significantly from baseline 
intake. 
Conclusion This study clearly shows that moderate amounts of fructose and sucrose 
significantly alter hepatic insulin sensitivity and lipid metabolism compared to similar 
amounts of glucose.  
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Trial registration: This trial has been registered at ClinicalTrials.gov under the registration Nr. 
NCT01021969. 
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Introduction 
In the USA, the consumption of fructose has increased by more than 25% between 1970 and 
1997 as the total sugar intake of the population rose (1). During the same time period, the 
prevalence of obesity has risen dramatically, paralleling the increase in fructose consumption 
and the introduction of high fructose corn syrup (2). Whether there is a causal relationship 
between those developments, however, remains unclear. Total fructose consumption from 
natural and added sources, estimated from food disappearance data, was estimated to be 97 
g/person/day in 1997 in the US (1) and 83 g/person/day in 1998 in Switzerland (3). 
In both epidemiological and intervention studies fructose and other caloric sweeteners have 
shown detrimental effects on health. In a cross-sectional study in US adults, for example, the 
consumption of caloric sweeteners was associated with increased dyslipidemia (4) and in the 
Health Professional Follow-up Study high intakes of sugar-sweetened beverages (SSB) were 
found to increase the risk for type 2 diabetes (5). Intervention trials have provided evidence 
that high to very high fructose doses lead to increases in de novo lipogenesis, blood 
triglycerides and hepatic insulin resistance (6-8). But not all of these studies found consistent 
effects for all parameters. In the study by Le et al., where 1.5 g of fructose/kg body weight 
were consumed over a period of four weeks, fasting lipids as well as glucose were affected, 
while insulin resistance as determined by a euglycemic-hyperinsulinemic clamp did not 
change. However, in this study only fructose was tested without comparison to other sugars 
(6). Furthermore, in most of these studies relatively high amounts of fructose were consumed, 
reaching up to 25% of total energy intake. In a recent intervention study in healthy Swiss men 
we have found adverse effects of low to moderate amounts of fructose, but also glucose and 
sucrose on fasting glucose and inflammatory markers, while only fructose containing 
beverages seemed to affect LDL particle size negatively. Even though fasting glucose was 
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altered, none of the interventions showed any effect on glucose tolerance, nor on indices of 
insulin sensitivity calculated during an oral glucose tolerance test (9).  
The aim of the present study was therefore to assess the effect of moderate amounts of 
fructose and sucrose compared to the same amounts of glucose specifically on hepatic insulin 
sensitivity, but also lipid profiles of healthy human subjects using euglycemic-
hyperinsulinemic clamps with [6,6]-
2
H2 labeled glucose. 
 
Subjects and Methods 
Study Design 
The study consisted of four different interventions in random sequence. Each of the 
interventions lasted three weeks and was directly followed by an examination in our clinic. 
Thereafter, a wash-out period of a minimum of four weeks was implemented before the 
beginning of the next intervention. The first subject started the study in February 2009 and the 
last subject completed the study in March 2011. During each intervention subjects were 
supplied with SSB containing different sugars in different concentrations: 40 g fructose/day 
(medium fructose, MF), 80 g fructose/day (high fructose, HF), 80 g glucose/day (high 
glucose, HG), and 80 g sucrose/day (high sucrose, HS). The drinks were provided in 
containers of 200 ml each, with blinded content, and the subjects had to consume three drinks 
(=600 ml) per day. The sugar concentrations of the drinks were 66.5 g/l and 133.5 g/l for the 
medium and high concentrations, respectively. Subjects were advised to consume the drinks 
together with the three main meals. To assess compliance subjects were asked to return 
beverages not consumed on the day of visit to the metabolic ward. The drinks were produced 
by the Nestlé Product Technology Center (PTC) in Konolfingen, Switzerland, under good 
manufacturing practice (GMP) conditions and according to our instructions. Prior to their use 
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in the study the drinks underwent quality control at the PTC. During the study, sugar content 
of the drinks was monitored and found to be stable. The order of the four different 
interventions was randomly assigned to the subjects (physical randomization) and the study 
was carried out in a double-blind manner with intention to treat analysis of the data. The 
random allocation of the order of interventions was carried out by a co-worker not otherwise 
involved in the study. Participants as well as the nurse taking the anthropometric 
measurements and the laboratory technicians were blinded to the order of interventions. 
Subjects 
Nine healthy, normal weight male volunteers (BMI between 20 and 24 kg/m
2
, age between 21 
and 25 years) living in the region of Zurich, Switzerland, were included in this study. Subjects 
were recruited through advertisements at the Universities in Zurich by IA. Written informed 
consent was obtained from all subjects prior to entering the study. The study was approved by 
the Ethics Committee of the University Hospital Zurich and registered under 
ClinicalTrials.gov (NCT01021969). Sample size calculation was based on an estimated 
difference in hepatic suppression between 2 interventions of 10% with a standard deviation of 
6% (alpha level 0.016 after Bonferroni correction for 3 comparisons) and determined a 
samples size of 9 volunteers to be sufficient. Volunteers were eligible for the study if they 
were male, had a normal BMI (19-25 kg/m
2
), were healthy and 20 to 50 years old. Volunteers 
taking regular medication or consuming SSB with a total content of more than 60g of 
carbohydrates per day were not included in the study. 
Protocol 
One day prior to each examination, subjects were asked not to engage in strenuous physical 
activity. On the examination day they were asked to present at the Clinical Trials unit of the 
University Hospital Zurich at 7.30 am after a 12 hour overnight fast. Upon arrival, weight was 
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determined to the nearest 100 g using a digital balance (WB 100 P, Tanita, Hoofddorp, The 
Netherlands) and height was measured to the nearest 0.5 cm using a wall mounted stadiometer 
at the first examination. BMI was calculated as weight (kg)/height (m)
2
. Waist and hip 
circumference were determined using a non-stretchable measuring tape. Percent body fat 
(%BF) was measured by bioelectrical impedance (AKERN BIA 101, AKERN, Pontassieve, 
Italy) in supine position.  
Blood pressure was measured using an automated device (Omron M6, upper arm blood 
pressure monitor) after a 15 min rest in supine position. Following this, with the subjects 
resting quietly in a bed, an indwelling catheter was inserted into the vein of the right arm for 
blood sampling. Another indwelling catheter was inserted into an antecubital vein of the left 
arm for the infusion of glucose, insulin and the tracer ([6,6]-
2
H2 glucose). In the fasted state, 
blood samples were collected for the measurement of glucose, insulin, C-peptide, lipid 
profile, and leptin. Following blood sampling, a primed continuous infusion of [6,6]-
2
H2 
glucose was administered during 5h to determine endogenous glucose production (bolus of 2 
mg/kg over 10 minutes, followed by a continuous rate of 0.02 mg/kg/min). After 180 min of 
tracer equilibration, a hyperinsulinemic-euglycemic clamp was started for the following 120 
min. Insulin was infused continuously (bolus of 60 mU/m
2
/min insulin for 3 minutes followed 
by continuous rate of 15 mU/m
2
/min). A relatively low insulin infusion rate with incomplete 
suppression of hepatic glucose production was chosen to reveal differences in insulin 
sensitivity in our generally insulin sensitive study group, and based on our previous 
experiences (10). Blood samples were collected every 5 minutes during the clamp to monitor 
blood glucose concentrations, and glucose (20 % wt/vol) was infused at variable rates to keep 
the blood glucose euglycemic (around 4.5 mmol/l) (Table 2). The 20% glucose infusion 
contained 1.2 % [6,6]-
2
H2 glucose to maintain a constant plasma D2-glucose tracer/trace ratio 
(TTR) during the clamp. Blood was drawn at time points 150, 165 and 180 min of the 3h 
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tracer equilibration (baseline) period, and at 60, 90, 105 and 120 min of the 2h clamp period 
for the determination of tracer concentrations (TTR = tracer/tracee ratio of [6,6]-
2
H2 glucose). 
Glucose kinetics were calculated as described previously (11) at near steady state at the end of 
the tracer equilibration baseline period (150 – 180min), and during the last 30 min of the 
clamp (mean values from time points given above). Total glucose flux (Ra), endogenous 
glucose production rate (EGP), glucose metabolic clearance rate (Rd divided by the glucose 
concentration, i.e. insulin mediated glucose disposal, a standard parameter of whole body 
insulin sensitivity) and % hepatic suppression of glucose production (a parameter of hepatic 
insulin sensitivity) were calculated as follows:  
Ra = F / TTR, with F being the rate of tracer infusion; EGP = Ra – glucose infusion rate; 
glucose metabolic clearance rate = Rd / glucose concentration = Ra / glucose concentration;  
Hepatic suppression = 100%*(( EGPbasal -  EGPclamp)/ EGPbasal).  
In the week prior to each examination as well as before the start of the first intervention, all 
subjects filled in a three day (two weekdays and one weekend day) weighed food record (12). 
During those three days all foods and drinks consumed had to be weighed on a digital kitchen 
scale whenever possible and, if not possible, amounts had to be documented in standard 
kitchen measures to allow quantitative estimation of dietary intake. Subjects were asked not to 
change their usual eating habits during the days of recording. 
The individual three day food records of each subject were carefully checked at the day of the 
examination to ensure completeness and comprehensibility. Data was then entered into a 
nutrition software system (EBISpro for Windows 8.0 (Swiss version), Dr. J. Erhardt, 
University of Hohenheim, Germany) to convert the amount of food eaten into individual 
nutrients. Three day energy and nutrient intakes were averaged to obtain a mean daily energy 
and nutrient intake for each subject.  
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Free fructose and free glucose refer to fructose and glucose that is contained in the food as 
monosaccharide, while total fructose and total glucose refer to both the monosaccharides and 
the part derived from the disaccharide sucrose (50% fructose and 50% glucose). 
The primary outcome measure of this trial was the change in insulin sensitivity, determined as 
the hepatic glucose suppression during the euglycemic-hyperinsulinemic clamp after fructose 
and sucrose interventions compared to glucose. Secondary outcome measures were changes 
fasting concentrations of lipids as well as glucose, insulin and C-peptide as well as changes in 
anthropometric measures. 
Laboratory Analysis 
Blood glucose was directly measured from whole blood samples (both fasting and during the 
clamp) using an automated enzymatic method (YSI 2300, YSI Life Sciences, Yellow Springs, 
USA). The remaining blood samples were centrifuged and the serum and plasma were either 
directly processed (lipid profile) or stored at -20°C for further analysis. Triglycerides, 
cholesterol and free fatty acids were measured in fresh serum on Roche MODULAR by 
enzymatic reactions (Triglyceride GPO-PAP and cholesterol CHOP-PAP; Roche Diagnostics, 
Mannheim, Germany), on Roche INTEGRA by a homogenous enzymatic color reaction 
(HDL-cholesterol plus 3rd generation; Roche Diagnostics, Mannheim, Germany) and on 
Konelab (Free Fatty Acidy, Thermo Scientific, Dreieich, Germany). From frozen serum, C-
peptide was measured using RIA (IRMA-C-PEP, CIS bio international, Bagnols-sur-Cèze 
Cedex, France), leptin using ELISA (EZHL-80 SK, Linco Research, Inc., St. Charles, USA). 
Plasma [6,6]-
2
H2 glucose enrichment (tracer / tracee ratio ;TTR) was measured by gas 
chromatography-mass spectrometry (Hewlett-Packard Instruments, Palo Alto, CA) as 
described elsewhere (13). 
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Statistical Analysis 
Statistical analysis was performed using the statistical package SPSS 19.0 (SPSS inc, IBM, 
Chicago, Illinois, USA). All variables were checked for normal distribution prior to data 
analysis. Data are expressed as arithmetic mean ± SD for normally distributed variables and 
as geometric mean ± SD for non-normally distributed data. Non-normally distributed data 
were log-transformed and further analysis carried out with the transformed data. According to 
the intention to treat design of the study, all subjects (completers and non-completers) were 
included in the final analysis. The effect of the interventions as well as of the order of the 
interventions on anthropometric and metabolic parameters was examined using multiple 
linear regression (as described in (14)), always controlling for between-patient differences. 
Post-hoc Bonferroni correction was applied to account for multiple comparisons. In the main 
analysis the three other interventions were compared to the glucose intervention, and thus a 
correction factor of 3 (3 interventions) was used. For the dietary intake all 4 interventions 
were compared to baseline, and thus a correction factor of 4 was used. A p-value of <0.05 
after correction was considered significant. 
 
Results  
A total of 9 subjects participated in the study. Except for one, who was not able to finish the 
last intervention (MF) because he moved abroad, all subjects completed all four interventions. 
Mean age of the subjects at baseline was 22.8 ± 1.7 years and their anthropometric 
characteristics after each of the interventions are shown in Table 1. Compared to the HG 
intervention, body weight, BMI, body fat and waist circumference were slightly but 
significantly lower after the HF intervention (p<0.05, GLM with bonferroni correction for 3 
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comparisons). Body weight and BMI were also significantly lower after the MF intervention 
compared to HG (p<0.01). 
The results of the euglycemic hyperinsulinemic clamps after each intervention are shown in 
Table 2. The hepatic suppression of glucose production during the clamp was significantly 
lower after the HF intervention compared to HG (p=0.015), as also shown by the higher ratio 
of endogenous production during the clamp / baseline (p=0.009), while there was no 
difference between HG and MF or HS (compare Figure 1). This shows a significant decrease 
in hepatic insulin sensitivity after relatively small amounts of daily fructose consumption. In 
contrast, no significant differences between diets were seen in glucose metabolic clearance 
rate, i.e. insulin mediated glucose clearance, which is a parameter of whole body insulin 
sensitivity. Mean glucose levels during the baseline measurements and the clamp were kept in 
the same range. 
Also shown in Table 1 are the fasting metabolic characteristics (glucose, insulin, C-peptide, 
lipids) of the subjects after each intervention. Fasting levels of glucose, insulin and C-peptide 
did not differ significantly between HG and any of the other interventions. Compared to the 
HG intervention, both LDL cholesterol and total cholesterol were significantly higher after the 
MF, HF and HS interventions (p<0.05). Furthermore, the free fatty acid concentration was 
increased after MF compared to HG (p=0.033), with a trend towards higher values after HF, 
and HS, albeit not significant. No differences were seen between the interventions for HDL 
cholesterol or triglycerides. 
Compared to HG (2.02 ± 2.28 ng/ml) leptin concentrations were significantly lower after MF 
(1.26 ± 1.22 ng ml, p=0.012) and HF (1.37 ± 2.54 ng/ml, p=0.012), while the difference to HS 
(1.71 ± 2.99 ng/ml) was not significant. 
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Dietary intake was assessed at baseline as well as after each of the 4 interventions. The 
consumption of energy, macronutrients, fibers as well as the different sugars are shown in 
Table 3 Energy intake as well as the % energy from fat, carbohydrates and protein did not 
differ significantly between HG and any of the other interventions, neither did fiber intake. 
However, protein intake was significantly lower in all interventions except for HS compared 
to baseline, while fat intake was significantly lower in the MF and the HS interventions, again 
compared to baseline. Carbohydrate intake was higher in the HF, HG and HS interventions 
compared to baseline, but the differences were not significant. The consumption of the 
individual sugars varies according to the interventions. 
 
Discussion 
This study has investigated the effect of sweetened beverages containing fructose or sucrose 
compared to those containing glucose and has resulted in two important findings: 1) 
Compared to HG, suppression of endogenous glucose production is reduced after the HF diet 
during the euglycemic hyperinsulinemic clamp, indicating reduced hepatic insulin sensitivity 
after the HF diet; 2) after all fructose containing diets (MF, HF and HS), both total and LDL-
cholesterol were elevated compared to HG.  
Glucose and fructose have a similar caloric content, but intermediary fructose metabolism has 
unique features. After a dietary fructose load, fructose is rapidly cleared from the plasma and 
efficiently metabolized in the liver in an insulin independent manner (2). While glucose 
metabolism via hexokinase and glycolysis is tightly regulated by the energy status of the cell 
and insulin levels, fructose metabolism via fructokinase bypasses these regulatory steps. 
Hence, rapid breakdown of fructose into trioses leads to high fluxes through the downstream 
steps of the glycolytic pathway, generating e.g. precursors and substrates for de novo 
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lipogenesis. Fructose ingestion also affects lipid metabolism via enhanced and extended 
activity of regulator proteins (e.g. SREBP-1c for de novo lipogenesis) (1, 8, 15, 16).  
Several studies have shown that supplementation with high amounts of fructose, associated 
with excess energy intake, induce features similar to those encountered in the metabolic 
syndrome. The most striking effect is an increase in fasting and post-prandial triglycerides, 
which can be explained by a stimulation of hepatic de novo lipogenesis (8, 17), a stimulation 
of VLDL-TG secretion, and a decreased VLDL-TG clearance (18, 19). In addition several 
studies have reported a mildly impaired hepatic insulin sensitivity, as indicated by an increase 
in fasting hepatic glucose production or by a blunted suppression of glucose production 
during hyperinsulinemia, or a deposition of ectopic fat in liver cells(7, 17, 20). 
In the present study, we have observed that, even with relatively small amounts of daily 
fructose consumption, there was a significant decrease in hepatic insulin sensitivity. This 
could be documented by using insulin clamp at low insulin infusion rates, which incompletely 
suppressed hepatic glucose production. In addition care was taken to have a long tracer 
infusion time prior to measurement to avoid erroneous results linked to incomplete tracer 
equilibration, which may explain why similar results had not been observed with former 
experiments (6). This clearly indicates that hepatic insulin sensitivity is exquisitely sensitive 
to fructose intake. The mechanisms underlying these effects remain unknown, but may 
involve a stimulation of gluconeogenesis and increased glycogen stores, or may be related to 
hepatic lipotoxicity. 
In contrast to this impaired hepatic insulin sensitivity, whole body (presumably essentially 
muscle) insulin sensitivity was not significantly altered by fructose-containing drinks. This is 
consistent with other studies having used higher amounts of fructose (7, 17), but may appear 
at odds with the observation that high fructose intakes can impair glucose tolerance. This 
strongly suggests that this impaired glucose tolerance is explained by impaired suppression of 
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hepatic glucose output rather than by muscle insulin resistance, at least with short term high 
fructose diets. It remains however possible that fructose administration over longer periods of 
time may also alter muscle insulin sensitivity, possibly through a progressive deposition of 
ectopic fat in skeletal muscle, as shown by Le et al. (7).  
In contrast to other studies (6, 21), we did not observe a significant increase in plasma 
triglyceride concentrations. This is most likely related to the relatively low amount of fructose 
administered in the present study. Based on a meta-analysis (22) fasting triglyceride 
concentrations increase with daily fructose intake above 100g/day, ie somewhat higher than 
used in the present experiments. However, interestingly, we have found an increase in total 
and LDL-cholesterol concentrations after the HF, MF, and HS diets compared to HG. 
Similarly, the study by Bantle et al. revealed differences in total and LDL-cholesterol between 
fructose and glucose diets after a study duration of 4 weeks, but they were no longer 
significant after 6 weeks, which was the study endpoint. At this point the only parameter 
which did differ between the glucose and fructose diets was triglyceride concentration in men 
(21). However, despite similar amounts of fructose and glucose, the study population in this 
trial was not necessarily comparable to the one in the present study. While in our study all 
subjects were aged between 20 and 25 years, in the study by Bantle et al. half of the subjects 
were aged above 40 years. Further, the mean BMI of our healthy volunteers was 22.3 kg/m2 
at baseline, while it was 24.7 and 25.8 kg/m2 in the subjects below and above 40 years of age 
respectively in the study by Bantle et al (21). Following along the same line, another recent 
study investigating the effect of different sugars on lipid metabolism reported results 
comparable to those we found, despite methodological differences (25% of energy 
requirements given as SSB, duration 2 weeks). This group observed increased concentrations 
of LDL-cholesterol, but also of 24-hour triglyceride area under the curve (a parameter we did 
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not assess) after fructose and high fructose corn syrup but not after glucose consumption 
while fasting triglycerides were similar after all interventions (23).  
A special feature of the present study is that it provided a direct comparison of the effects of 
fructose-containing drinks to glucose alone. Only few studies have performed such a direct 
comparison. Stanhope et al. found an increase in fasting glucose and a decrease in insulin 
sensitivity after a 10-week intervention with fructose containing beverages but not after 
glucose containing beverages (8). However, in this study, the energy provided by the fructose 
and glucose beverages accounted for 25% of total energy intake. In our study diminished 
hepatic insulin sensitivity could be seen despite a considerably lower amount of sugar given 
(15% of baseline energy intake) and a much shorter study duration. This indicates that already 
relatively low amounts of fructose over a short period of time may negatively affect glucose 
metabolism even in healthy lean subjects. In disagreement to our results, recent studies by 
Silbernagel et al. and Ngo Sock et al. found similar effects of high glucose and high fructose 
diets with regard to insulin sensitivity determined by oral glucose tolerance test (24) or to 
intrahepatic fat content (20); There was, however, a significant increase in fasting triglyceride 
concentrations with fructose only. 
Compared to the glucose intervention, we found significantly lower weight and BMI 
following the MF and HF intervention and significantly lower body fat and waist 
circumference after HF only. Even though the differences were relatively small, the finding 
was consistent over the different anthropometric measurements and could not be explained by 
higher energy intake during the HG intervention or by reduced physical activity. One previous 
study comparing weight and fat changes after high fructose and high glucose diets found that, 
even though overall weight gain was similar, fructose induced more gain in intra-abdominal 
adipose tissue, while glucose led to increased subcutaneous adipose tissue (8). The duration of 
the interventions in this study, however, was 10 weeks, and 25% of energy requirements were 
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provided in the form of sugar. We did not distinguish between intra-abdominal and 
subcutaneous adipose tissue in our study and can therefore not be sure what the changes we 
have observed were attributable to. However, it has been shown in previous studies, that 
leptin is mainly secreted in subcutaneous adipose tissue (25, 26). Thus, the increased secretion 
of leptin after HG compared to HF and MF we have observed also points towards an increase 
in subcutaneous adipose tissue after this intervention. The small sample size in our study and 
the relatively short study duration may have blunted other changes seen in previous studies. 
A limitation of the present study may be the relatively short duration of the interventions and 
the moderate amount of sugars given. However, our aim was to study the effect of the 
different sugars in amounts that are likely to be consumed in normal life. And the fact that we 
did see certain effects already at this level and after three weeks seems to justify our decision. 
Another limitation is the lack of baseline measurements prior to each of the interventions. 
Still, based on the complexity of the method used and the already high subject burden, we 
decided against them. However, to control for possible baseline differences we used a 
randomized cross-over design and controlled for the order of interventions in the statistical 
analysis.   
In conclusion, this study shows that, with regard to glucose metabolism and specifically 
hepatic insulin sensitivity, fructose, even in moderate amounts, seems to be more harmful 
than the same amount of glucose. Furthermore, all fructose-containing drinks (including 
sucrose) showed significant effects on the lipid profile when compared to glucose. On the 
other hand, anthropometric measurements pointed towards higher adiposity after the glucose 
intervention, even though differences were small. Thus, even when consumed in moderate 
amounts and over a limited period of time, SSB, especially those containing fructose, can 
result in alterations of hepatic glucose metabolism and lipid profile in healthy young men, 
which may possibly be associated with increased cardiometabolic risk. Further research will 
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be needed to better understand the underlying mechanisms, specifically with regard to the 
lipid metabolism, and also to understand other influencing factors such as age, gender or 
genetic predisposition. 
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Table 1 Anthropometric characteristics as well as fasting glucose, insulin, C-peptide and lipid 
concentrations of all subjects after each of the four 3-week interventions 
 HG MF HF HS 
N 9 8 9 9 
Anthropometrics     
Weight (kg)
 1
 74.1 ± 7.1 72.0 ± 7.7
3
 72.3 ± 6.9
3
 73.4 ± 7.1 
Height (m)
 1
 1.80 ± 0.08 1.80 ± 0.08 1.80 ± 0.08 1.80 ± 0.08 
BMI (kg/m
2
)
 1
 22.8 ± 1.4 22.3 ± 1.5
3
 22.3 ± 1.3
3
 22.6 ± 1.1 
Waist circumference 
(cm)
 1
 
83.3 ± 6.2 83.1 ± 6.1 82.9 ± 6.1
3
 83.3 ± 5.8 
Body fat (%)
1
 16.8 ± 2.8 16.7 ± 2.5 15.8 ± 2.2
3
 16.3 ± 2.0 
Body fat (kg)
 1
 12.5 ± 3.3 12.2 ± 3.0 11.3 ± 2.0
3
 12.1 ± 2.5 
Fasting glucose 
metabolism 
    
Fasting glucose
 
(mmol/l)
 1
 
4.24 ± 0.26 4.29 ± 0.33 4.33 ± 0.256 4.32 ± 0.28 
Insulin
 
(pmol/l)
 1
 105.4 ± 36.2 89.6 ± 22.0 113.8 ± 37.3 105.1 ± 20.4 
C-peptide (pmol/l)
 1
 548.9 ± 127.5 499.4 ± 86.4 535.6 ± 119.2 512.2 ± 93.6 
Lipids     
Total cholesterol 
(mmol/l)
1
 
3.48 ± 0.69 3.65 ± 0.59
3
 3.72 ± 0.68
3
 3.76 ± 0.77
3
 
HDL-C (mmol/l)
2
 1.16 ± 0.23 1.18 ± 0.21 1.21 ± 0.28 1.22 ± 0.23 
LDL-C (mmol/l)
2
 1.85 ± 0.57 2.03 ± 0.54
3
 2.02 ± 0.57
3
 2.08 ± 0.68
3
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Triglycerides 
(mmol/l)
2
 
0.77 ±0.40 0.65 ± 0.58 0.79 ± 0.41 0.71 ± 0.31 
Free fatty acids 
(μmol/l)1 
419.3 ± 236.1 578.6 ± 
230.1
3
 
457.0 ± 117.3 506.0 ± 269.8 
1
 arithmetic mean ± SD 
2
 geometric mean ± SD 
3
 significantly different compared to HG (p<0.05, multiple linear regression with bonferroni 
correction for 3 comparisons) 
correction for 3 comparisons) 
HG: 80 g glucose/day, MF: 40 g of fructose/day, HF: 80 g of fructose/day, HS: 80 g of 
sucrose per day 
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Table 2 Glucose metabolism during the clamp in all subjects after each of the four 3-week 
interventions 
 HG MF HF HS 
N 9 8 9 9 
Glucose 
concentrations 
    
Glucose Baseline 
(BL)
1
(mmol/l) 
4.30 ± 0.23 4.17 ± 0.17 4.34 ± 0.28 4.48 ± 0.50 
Glucose 
Clamp
2
(mmol/l) 
4.50 ± 0.19 4.40 ± 0.40 4.71 ± 0.42 4.51 ± 0.28 
Hepatic 
suppression 
    
Clamp (%) 70.3 ± 10.5 72.3 ± 21.9 59.4 ± 11.0
3
 72.7 ± 12.1 
Endogenous 
glucose production 
rate (EGP) 
    
Clamp
 
( /kg*min) 
3.15 ± 1.17 3.49 ± 2.06 4.17 ± 1.37 3.25 ± 1.00 
BL
 
( /kg*min)
 
 10.53 ± 0.99 10.42 ± 1.01 10.23 ± 1.52 10.64 ± 1.10 
Clamp/BL 0.30 ± 0.10 0.31 ± 0.18 0.41 ± 0.11
3
 0.30 ± 0.07 
Metabolic 
clearance rate 
(glucose) 
    
Clamp
 
(ml/kg*min) 5.53 ± 1.43 5.60 ± 2.25 5.71 ± 2.58 5.67 ± 1.62 
BL
 
(ml/kg*min) 
 
2.52 ± 0.22 2.53 ± 0.31 2.41 ± 0.30 2.47 ± 0.42 
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Clamp/BL 2.20 ± 0.55 2.28 ± 1.04 2.37 ± 0.98 2.29 ± 0.45 
Total Flux (Ra)     
Clamp 
( *min) 
24.6 ± 6.05 24.2 ± 7.71 26.1 ± 10.50 25.1 ± 6.66 
BL
 
( *min)
 
 10.7 ± 1.00 10.6 ± 1.02 10.4 ± 1.53 10.8 ± 1.11 
Clamp/BL 2.30 ± 0.56 2.33 ± 0.87 2.56 ± 1.00 2.31 ± 0.49 
arithmetic mean ± SD (all values) 
1
 mean value at the end of the tracer equilibration period (baseline) at time points 150, 165, 
180min 
2
 mean value at the end of the 2h clamp period at timepoints 90, 105 and 120 min. 
3
 significantly different compared to HG (p<0.05, multiple linear regression with bonferroni 
correction for 3 comparisons) 
Glucose kinetics are calculated in near steady state at the end of the tracer equilibration period 
(= baseline period, BL) and the clamp period as described in ‘materials and methods’. 
HG: 80 g glucose/day, MF: 40 g of fructose/day, HF: 80 g of fructose/day, HS: 80 g of 
sucrose per day 
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Table 3 Dietary intake (mean ± SD) of all subjects at baseline and after each of the four 3-
week interventions 
 Baseline HG MF HF HS 
N 9 9 8 9 9 
Energy 
(kcal/d) 
2108 ± 469 2187 ± 497 1830 ± 766 2338 ± 335 2141 ± 349 
% Carbs 49 ± 8.5 54 ± 5.3 47 ± 18.5 56 ± 5.0 54 ± 6.1 
% Protein 17 ± 3.5 14 ± 1.7
1
 13 ± 5.4
1
 13 ± 2.0
1
 16 ± 3.4 
% fat 34 ± 6.9 31 ± 5.1 29 ± 11.7
1
 31 ± 4.3 30 ± 5.8
1
 
Free fructose 
(g/d) 
14.9 ± 6.5 7.8 ± 6.3
1
 51.2 ± 5.9
1,2
 88.2 ± 4.8
1,2
 9.5 ± 4.9 
Total fructose 
(g/d) 
40.3 ± 15.4 27.7 ± 11.2
1,2
 77.3 ± 13.9
1,2
 110.2 ± 8.8
1,2
 71.5 ± 17.3
1,2
 
Free glucose 
(g/d) 
13.8 ± 5.8 89.3 ± 4.7
1,2
 7.8 ± 3.9
2
 7.2 ± 3.5
1,2
 8.2 ± 4.0
2
 
Total glucose 
(g/d) 
39.2 ± 14.9 109.2 ± 7.8
1,2
 33.9 ± 14.7
1,2
 29.2 ± 8.3
1,2
 68.5 ± 16.1
1,2
 
Sucrose (g/d) 50.8 ± 23.4 39.6 ± 14.9 52.2 ± 27.4 44.0 ± 15.1 117.1 ± 
21.4
1,2
 
Fibers (g/d) 22.7 ± 11.0 17.5 ± 8.4 18.3 ± 5.9 19.8 ± 7.0 16.5 ± 5.9 
Ariithmetic mean ± SD (all values) 
1
 significantly different compared to baseline (p<0.05, multiple linear regression with 
bonferroni correction for 4 comparisons) 
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2
 significantly different compared to HG (p<0.05, multiple linear regression including MF, 
HF, HG and HS with bonferroni correction for 3 comparisons) 
HG: 80 g glucose/day, MF: 40 g of fructose/day, HF: 80 g of fructose/day, HS: 80 g of 
sucrose per day 
 27 
 
 
Figure legend 
Figure 1 Hepatic suppression of glucose production (%) after three weeks consumption of 
different sugar sweetened beverages (HG: 80 g glucose/day, MF: 40 g fructose/day, HF: 80 g 
fructose/day, HS: 80 g sucrose/day). * significantly different from HG, p<0.05. Values are 
means ± 1 SD. 
 
 
